Advertisement
Research Article

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

  • Franco Lori mail,

    info@virostatics.it

    Affiliation: ViroStatics srl, Alghero, Italy

    X
  • Davide De Forni,

    Affiliation: ViroStatics srl, Alghero, Italy

    X
  • Elly Katabira,

    Affiliation: Makerere Medical School, Kampala, Uganda

    X
  • Denis Baev,

    Affiliation: ViroStatics srl, Alghero, Italy

    X
  • Renato Maserati,

    Affiliation: Infectious Diseases Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy

    X
  • Sandra A. Calarota,

    Affiliation: ViroStatics srl, Alghero, Italy

    Current address: Virology and Microbiology Department of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

    X
  • Pedro Cahn,

    Affiliation: Fundación Huesped, Buenos Aires, Argentina

    X
  • Marco Testori,

    Affiliation: ViroStatics srl, Alghero, Italy

    Current address: Bavarian Nordic GmbH, Martinsried, BSL Bioservice Scientific Laboratories GmbH, Munich, Germany

    X
  • Aza Rakhmanova,

    Affiliation: Department of Infectious Diseases, St. Petersburg Health Department, St. Petersburg, Russia

    X
  • Michael R. Stevens

    Affiliation: ViroStatics srl, Princeton, New Jersey, United States of America

    X
  • Published: October 19, 2012
  • DOI: 10.1371/journal.pone.0047485

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.